|Articles|March 23, 2017
Medidata Platform Selected for Leukemia Trial
Medidata announced that The Leukemia & Lymphoma Society has selected Medidata’s Clinical Cloud platform to power its trial for acute myeloid leukemia (AML).
Advertisement
Medidata announced that The Leukemia & Lymphoma Society has selected Medidata’s Clinical Cloud platform to power its trial for acute myeloid leukemia (AML). Medidata is also incorporating its EDC, management and reporting solution, Medidata Rave, and its medical coding solution, Medidata Coder, to this trial.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Operational Strategies That Strengthened the NIMBLE Trial DesignSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Generative AI Transforms Clinical Study Report Development
2
Atom Therapeutics Launches Global Phase II Trial of Novel Anti-Inflammatory Treatment for Acute Gout Flares
3
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
4
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
